vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
RE/MAX Holdings, Inc. is the larger business by last-quarter revenue ($71.1M vs $47.7M, roughly 1.5× IRONWOOD PHARMACEUTICALS INC). RE/MAX Holdings, Inc. runs the higher net margin — 2.0% vs -4.8%, a 6.8% gap on every dollar of revenue. On growth, RE/MAX Holdings, Inc. posted the faster year-over-year revenue change (-1.8% vs -47.3%). IRONWOOD PHARMACEUTICALS INC produced more free cash flow last quarter ($74.6M vs $33.5M). Over the past eight quarters, RE/MAX Holdings, Inc.'s revenue compounded faster (-4.7% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
IRWD vs RMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $71.1M |
| Net Profit | $-2.3M | $1.4M |
| Gross Margin | — | — |
| Operating Margin | 14.3% | 13.1% |
| Net Margin | -4.8% | 2.0% |
| Revenue YoY | -47.3% | -1.8% |
| Net Profit YoY | -200.9% | -75.2% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.7M | $71.1M | ||
| Q3 25 | $122.1M | $73.2M | ||
| Q2 25 | $85.2M | $72.8M | ||
| Q1 25 | $41.1M | $74.5M | ||
| Q4 24 | $90.5M | $72.5M | ||
| Q3 24 | $91.6M | $78.5M | ||
| Q2 24 | $94.4M | $78.5M | ||
| Q1 24 | $74.9M | $78.3M |
| Q4 25 | $-2.3M | $1.4M | ||
| Q3 25 | $40.1M | $4.0M | ||
| Q2 25 | $23.6M | $4.7M | ||
| Q1 25 | $-37.4M | $-2.0M | ||
| Q4 24 | $2.3M | $5.8M | ||
| Q3 24 | $3.6M | $966.0K | ||
| Q2 24 | $-860.0K | $3.7M | ||
| Q1 24 | $-4.2M | $-3.4M |
| Q4 25 | 14.3% | 13.1% | ||
| Q3 25 | 61.8% | 25.0% | ||
| Q2 25 | 53.2% | 19.3% | ||
| Q1 25 | -70.7% | 7.2% | ||
| Q4 24 | 34.8% | 5.9% | ||
| Q3 24 | 28.0% | 19.4% | ||
| Q2 24 | 26.5% | 20.6% | ||
| Q1 24 | 14.7% | 5.8% |
| Q4 25 | -4.8% | 2.0% | ||
| Q3 25 | 32.8% | 5.4% | ||
| Q2 25 | 27.7% | 6.4% | ||
| Q1 25 | -90.9% | -2.6% | ||
| Q4 24 | 2.5% | 8.0% | ||
| Q3 24 | 4.0% | 1.2% | ||
| Q2 24 | -0.9% | 4.7% | ||
| Q1 24 | -5.6% | -4.3% |
| Q4 25 | $0.01 | — | ||
| Q3 25 | $0.23 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $-0.23 | — | ||
| Q4 24 | $0.03 | — | ||
| Q3 24 | $0.02 | — | ||
| Q2 24 | $-0.01 | — | ||
| Q1 24 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $118.7M |
| Total DebtLower is stronger | — | $432.2M |
| Stockholders' EquityBook value | $-261.8M | $452.4M |
| Total Assets | $396.9M | $582.5M |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $215.5M | $118.7M | ||
| Q3 25 | $140.4M | $107.5M | ||
| Q2 25 | $92.9M | $94.3M | ||
| Q1 25 | $108.5M | $89.1M | ||
| Q4 24 | $88.6M | $96.6M | ||
| Q3 24 | $88.2M | $83.8M | ||
| Q2 24 | $105.5M | $66.1M | ||
| Q1 24 | $121.5M | $82.1M |
| Q4 25 | — | $432.2M | ||
| Q3 25 | $199.5M | $433.3M | ||
| Q2 25 | $199.3M | $434.4M | ||
| Q1 25 | $199.2M | $435.3M | ||
| Q4 24 | $199.0M | $436.2M | ||
| Q3 24 | $198.8M | $437.2M | ||
| Q2 24 | $198.6M | $438.1M | ||
| Q1 24 | $398.3M | $439.0M |
| Q4 25 | $-261.8M | $452.4M | ||
| Q3 25 | $-264.2M | $448.1M | ||
| Q2 25 | $-308.2M | $442.4M | ||
| Q1 25 | $-334.1M | $433.5M | ||
| Q4 24 | $-301.3M | $429.5M | ||
| Q3 24 | $-311.3M | $423.1M | ||
| Q2 24 | $-321.7M | $418.4M | ||
| Q1 24 | $-330.5M | $412.0M |
| Q4 25 | $396.9M | $582.5M | ||
| Q3 25 | $396.1M | $582.2M | ||
| Q2 25 | $342.9M | $574.8M | ||
| Q1 25 | $327.2M | $571.4M | ||
| Q4 24 | $350.9M | $581.6M | ||
| Q3 24 | $389.5M | $578.6M | ||
| Q2 24 | $395.6M | $571.4M | ||
| Q1 24 | $438.8M | $566.7M |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | $40.9M |
| Free Cash FlowOCF − Capex | $74.6M | $33.5M |
| FCF MarginFCF / Revenue | 156.3% | 47.1% |
| Capex IntensityCapex / Revenue | 0.0% | 10.4% |
| Cash ConversionOCF / Net Profit | — | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $40.9M | ||
| Q3 25 | $47.6M | $17.7M | ||
| Q2 25 | $-15.1M | $4.6M | ||
| Q1 25 | $20.0M | $5.7M | ||
| Q4 24 | $15.2M | $59.7M | ||
| Q3 24 | $9.9M | $17.6M | ||
| Q2 24 | $33.5M | $15.9M | ||
| Q1 24 | $45.0M | $9.4M |
| Q4 25 | $74.6M | $33.5M | ||
| Q3 25 | $47.6M | $16.4M | ||
| Q2 25 | $-15.1M | $2.9M | ||
| Q1 25 | $19.9M | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | $9.9M | $16.3M | ||
| Q2 24 | $33.4M | $14.0M | ||
| Q1 24 | $44.9M | $6.8M |
| Q4 25 | 156.3% | 47.1% | ||
| Q3 25 | 39.0% | 22.4% | ||
| Q2 25 | -17.7% | 4.0% | ||
| Q1 25 | 48.4% | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | 10.8% | 20.8% | ||
| Q2 24 | 35.4% | 17.8% | ||
| Q1 24 | 60.0% | 8.6% |
| Q4 25 | 0.0% | 10.4% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 2.2% | ||
| Q1 25 | 0.1% | 2.3% | ||
| Q4 24 | 0.0% | 9.1% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.1% | 2.4% | ||
| Q1 24 | 0.1% | 3.3% |
| Q4 25 | — | 28.39× | ||
| Q3 25 | 1.19× | 4.45× | ||
| Q2 25 | -0.64× | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.74× | 10.28× | ||
| Q3 24 | 2.71× | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRWD
Segment breakdown not available.
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
